secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0000950170-23-000514
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences reports preliminary Q4 2022 revenue ~$20.5M, up 40% YoY; CFO Selnick steps down, Rodberg interim
--------------------------------------------------------------------------------

- Preliminary Q4 2022 total revenue $20.4M-$20.6M (+40% YoY); full-year revenue $71.2M-$71.4M (+46% YoY).
- Surgical Glaucoma revenue Q4 $18.7M-$18.8M (+35% YoY); Dry Eye revenue $1.7M-$1.8M (+130% YoY).
- CFO Jesse Selnick stepped down effective Jan 9, 2023; will provide transition consulting. Jim Rodberg appointed interim CFO.
- Director Mack Hicks resigned from Board and Audit Committee; Dr. Tamara Fountain appointed to Audit Committee.
- Company expects to announce complete Q4 and FY2022 results in March 2023; results are preliminary and subject to audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023000514/0000950170-23-000514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023000514/sght-20230105.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer